Spartan Wealth Advisory Services LLC Invests $406,000 in Novo Nordisk A/S $NVO

Spartan Wealth Advisory Services LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the first quarter, HoldingsChannel reports. The firm purchased 11,057 shares of the company’s stock, valued at approximately $406,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at about $25,000. WealthCollab LLC increased its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $28,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Analyst Ratings Changes

Several brokerages recently issued reports on NVO. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Wolfe Research initiated coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Down 0.1%

NYSE:NVO opened at $50.29 on Monday. The firm has a 50-day simple moving average of $46.09 and a 200-day simple moving average of $45.79. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The firm has a market cap of $224.56 billion, a P/E ratio of 11.81, a P/E/G ratio of 4.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Equities analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.